Literature DB >> 12655570

Six novel ATM mutations in Italian patients with classical ataxia-telangiectasia.

Silvia Saviozzi1, Alessandro Saluto, Maria Piane, Sabrina Prudente, Nicola Migone, Mario DeMarchi, Alfredo Brusco, Luciana Chessa.   

Abstract

Mutations in the ATM gene are responsible for the autosomal recessive syndrome Ataxia Telangiectasia (AT). In a group of 26 classical AT Italian patients studied by protein truncation test (PTT), we identified six new mutations, never reported so far. Mutations -spread over the entire ATM coding sequence with not clear "hot-spot"- are four frameshifts (2192_2193insA, 3110delC, 7150delA, 8368delA), one splice site alteration (8850G>T, causing exon 63 skipping) and one nonsense change (6913C>T, Q2305X). The identification of ATM gene mutations is important for understanding the molecular basis of the disease, and is essential for diagnosis and genetic counseling. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12655570     DOI: 10.1002/humu.9129

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  2 in total

1.  A novel approach to describe a U1 snRNA binding site.

Authors:  Marcel Freund; Corinna Asang; Susanne Kammler; Carolin Konermann; Jörg Krummheuer; Marianne Hipp; Imke Meyer; Wolfram Gierling; Stephan Theiss; Thorsten Preuss; Detlev Schindler; Jørgen Kjems; Heiner Schaal
Journal:  Nucleic Acids Res       Date:  2003-12-01       Impact factor: 16.971

2.  Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition.

Authors:  Gianluca Tedaldi; Francesca Pirini; Michela Tebaldi; Valentina Zampiga; Ilaria Cangini; Rita Danesi; Valentina Arcangeli; Mila Ravegnani; Raefa Abou Khouzam; Chiara Molinari; Carla Oliveira; Paolo Morgagni; Luca Saragoni; Maria Bencivenga; Paola Ulivi; Dino Amadori; Giovanni Martinelli; Fabio Falcini; Guglielmina Nadia Ranzani; Daniele Calistri
Journal:  Cancers (Basel)       Date:  2019-09-11       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.